Sino Biopharma Unit to Present Results of Two Hepatitis B Virus Drugs at Liver Disease Conference
MT Newswires Live10-14
Sino Biopharmaceutical (HKG:1177) will orally present the results of a clinical study of TQ-A3334 at The Liver Meeting 2026 of the American Association for the Study of
Liver Diseases
The results were selected as a Late-Breaking Abstract for the conference, a Wednesday bourse filing showed.
The trial studied the safety and efficacy of the drug developed by unit Chia Tai Tianqing Pharmaceutical Group.
Additionally, Bepirovirsen, a product resulting from the strategic collaboration between Chia Tai Tianqing Pharmaceutical and GlaxoSmithKline was selected for two oral presentations and eight poster presentations, including one poster of distinction.
The two drugs were tested in participants with hepatitis B virus.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
